Climb Bio, Inc. Common Stock (CLYM) Stock Price

CLYMStock
$14.57+533.48%52W
Market Cap$836.85M
P/E
PEG Ratio
Div yield
Beta-0.02

CLYM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)117.16%
Price vs S&P 500 (4W)21.83%
VGM Score77.75

CLYM Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.21-$0.18+15.29%(+$0.03)
Q1 2026-$0.30-$0.20+33.58%(+$0.10)
Q4 2025-$0.21-$0.26-25.80%(-$0.05)
Q3 2025-$0.14-$0.19-31.03%(-$0.05)
Q2 2025-$0.18-$0.13+29.73%(+$0.05)

CLYM Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.42
4.40
4.43
4.45

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CLYMClimb Bio, Inc. Common Stock
B$14.57
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Climb Bio, Inc. Common Stock

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B cells for the treatment of B-cell-mediated diseases.